Payment overview · 2025
General Payments
$942.13
47 reported records · 14 companies
Healthcare provider profile · identity verified
Janet M Beebe, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · BOWIE, MD · NPI 1710981709
Verified facts
What the public records show
CMS Open Payments records show Janet M Beebe, CRNP received $942.13 in general payments during 2025 across 47 reported records.
Collegium Pharmaceutical, Inc. accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ubrelvy, Vraylar, Zubsolv.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
Orexo US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zubsolv as an associated drug or biological on 1867 records involving 794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Zubsolv by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $225.55 | 23.9% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $220.61 | 23.4% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $99.05 | 10.5% | 4 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $73.47 | 7.8% | 3 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $65.52 | 7.0% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $37.40 | 4.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $35.22 | 3.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $34.42 | 3.6% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $34.41 | 3.6% | 2 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $29.44 | 3.1% | 1 | 2025 |
| SPR Therapeutics, Inc | Unresolved — no canonical attribution shown | $25.52 | 2.7% | 1 | 2025 |
| Fidia Pharma USA Inc. | Unresolved — no canonical attribution shown | $24.36 | 2.6% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $23.50 | 2.5% | 1 | 2025 |
| Valinor Pharma, LLC | Unresolved — no canonical attribution shown | $13.66 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $942.13 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $206.29 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $137.54 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $99.05 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $99.05 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $83.07 | 5 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $73.47 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $65.67 | 4 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $48.62 | 3 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $37.40 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.22 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $34.42 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $34.41 | 2 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $29.44 | 1 | 2025 |
Source payment records
|
|||||
| SPRINT PNS System Normalized: sprint pns system |
Device | SPR Therapeutics, Inc | $25.52 | 1 | 2025 |
Source payment records
|
|||||
| HYMOVIS Normalized: hymovis |
Device | Fidia Pharma USA Inc. | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| MOVANTIK Normalized: movantik |
Drug | Valinor Pharma, LLC | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Zubsolv zubsolv |
2025 | Zubsolv | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Orexo US, Inc. Exact reporting entity; no affiliate inference |
2025 | Zubsolv open payments reported associated product |
CMS Open Payments — General Payments 1867 supporting records · 794 recipient NPIs · example record 1190507283 |
Zubsolv · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 174 | 39 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 114 | 16 |
| Gabapentin | Gabapentin | 92 | 26 |
| Alprazolam | Alprazolam | 60 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 56 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | 17 |
| Xtampza Er | Oxycodone Myristate | 56 | suppressed |
| Mirtazapine | Mirtazapine | 54 | 11 |
| Trazodone Hcl | Trazodone Hcl | 49 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 12 |
| Tramadol Hcl | Tramadol Hcl | 46 | 11 |
| Buprenorphine Hcl | Buprenorphine Hcl | 43 | suppressed |
| Meloxicam | Meloxicam | 43 | suppressed |
| Pregabalin | Pregabalin | 43 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Methocarbamol | Methocarbamol | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 32 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 29 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 26 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 18 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Losartan Potassium | Losartan Potassium | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Omeprazole | Omeprazole | 17 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 16 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 16 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 15 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Lisinopril | Lisinopril | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $942.13 · 47 records | Collegium Pharmaceutical, Inc. | BRIXADI, Belbuca, CAPLYTA, HYMOVIS, JOURNAVX, MOVANTIK, NURTEC ODT, QULIPTA, RELISTOR, SPRINT PNS System, SUBLOCADE, Senza, UBRELVY, VRAYLAR, VYEPTI, XTAMPZA, ZAVZPRET, Zubsolv | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ubrelvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error